Janux Therapeutics (JANX) Free Cash Flow (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Free Cash Flow of -$12.6 million for Q1 2026, up 25.53% year-over-year from -$10.0 million in Q1 2025, and up 53.86% quarter-over-quarter from -$27.3 million in Q4 2025.
Janux Therapeutics (JANX) Free Cash Flow (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Free Cash Flow for 7 consecutive years, with -$12.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 25.53% year-over-year to -$12.6 million; the TTM figure through Mar 2026 stood at -$77.6 million (down 68.46% YoY), while the FY2025 annual figure was -$82.0 million, down 85.47% from the prior year.
- Free Cash Flow improved to -$12.6 million in Q1 2026 per JANX's latest filing, from -$27.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$2.0 million in Q3 2024 and bottomed at -$27.3 million in Q4 2025.
- Historically, Free Cash Flow has averaged -$13.8 million across 5 years, with a median of -$12.6 million in 2026.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 83.49% — and 2025, when it plunged 553.66%.
- Janux Therapeutics' Free Cash Flow stood at -$12.2 million in 2022, then increased by 14.8% to -$10.4 million in 2023, then plunged by 63.77% to -$17.1 million in 2024, then slumped by 60.21% to -$27.3 million in 2025, then surged by 53.86% to -$12.6 million in 2026.
- Business Quant data shows JANX's Free Cash Flow at -$12.6 million in Q1 2026, -$27.3 million in Q4 2025, and -$12.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 13.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.35 Mn |
| Jun 30, 2026 | 13.35 Mn |
| Mar 31, 2026 | -12.61 Mn |
| Mar 31, 2026 | -12.61 Mn |
| Dec 31, 2025 | -27.33 Mn |
| Dec 31, 2025 | -27.33 Mn |
| Sep 30, 2025 | -12.95 Mn |
| Sep 30, 2025 | -12.95 Mn |
| Jun 30, 2025 | -24.75 Mn |
| Jun 30, 2025 | -24.75 Mn |
| Mar 31, 2025 | -16.93 Mn |
| Mar 31, 2025 | -16.93 Mn |
| Dec 31, 2024 | -17.06 Mn |
| Dec 31, 2024 | -17.06 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Jun 30, 2024 | -10.12 Mn |
| Jun 30, 2024 | -10.12 Mn |
| Mar 31, 2024 | -15.03 Mn |
| Mar 31, 2024 | -15.03 Mn |